Replies to post #1345 on Hepion Pharmaceuticals Inc (HEPA)

[Fress]

Chomp Chomp!!


HEPA CRV431 in Nash Phase 2A Preliminary Conclusions:

1. Reduction transaminases at 28 days what MDGL took 3 months to achieve signals early efficacy for HEPA CRV431 in F2/F3 Nash subjects.

2. HEPA CRV431 predicts reductions in serum alanine transaminase.

3. Trial simulations with HEPA's AIPOWR platform predict & suggest greater efficacy at 150mg and 225mg dose levels!

4. Bioinformatics with AI-POWR trademarked reveal reveal significant interactions with with collagen regulating genes.

5. Confirmation of these effects will be fully evaluated using the 225mg cohort and the final genomic & lipidomic, and biomarker data for a full simulation of the Phase2b Trial for NASH.


HEPA Tackling Nash & Chronic Liver Disease - CRV431 Mechanism of Action.

HEPA AI POWR Platform
https://hepionpharma.com/ai-powr/

HEPA website
https://hepionpharma.com

HEPA June 2021 Biz Presentation
https://hepionpharma.com/wp-content/uploads/2021/06/Corporate-deck-June-2021-FINAL.pdf


Former Novo Nordisk Executive, Dr. Todd M. Hobbs, Joins Hepion Pharmaceuticals as Chief Medical Officer
https://www.biospace.com/article/releases/former-novo-nordisk-executive-dr-todd-m-hobbs-joins-hepion-pharmaceuticals-as-chief-medical-officer/

HEPA a Billion dollar plus market cap in the making!


MDGL 1.8 Billion market cap
HEPA 160 Million market cap 120 Million in cash.

https://giphy.com/gifs/television-arena-political-hzrvwvnbgIV6E

$HEPA